(Updates with further details and background)
March 20 (Reuters) - Australian Clinical Labs (ACL) said on Monday it will acquire Healius (HLS) through an all-share takeover, valuing the medical center operator at A$1.52 billion ($1.02 billion).
The pathology firm said it will offer 0.74 share for every Healius share. The offer price represents a discount of about 4.2% to Healius' last close.
If the deal is successful, Healius' shareholder will own 68% of the merged entity, the company said in a statement.
In 2020, Healius rejected a $1.3 billion buyout offer from Partners Group, saying at the time it undervalued the medical center operator.
($1 = 1.4896 Australian dollars)
News: ACL UPDATE 1-Australian Clinical Labs offers to buy Healius for $1 billion
Add ACL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.25 |
Change
-0.030(1.32%) |
Mkt cap ! $454.1M | |||
| Open | High | Low | Value | Volume |
| $2.28 | $2.28 | $2.19 | $1.902M | 853.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4672 | $2.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.27 | 3500 | 1 |
View Market Depth
| Last trade - 16.10pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.26 |
Change
-0.030 ( 0.78 %) |
||||
| Open | High | Low | Volume | ||
| $2.28 | $2.28 | $2.20 | 141881 | ||
| Last updated 15.59pm 05/06/2024 ? | |||||
| ACL (ASX) Chart |